Milan

• A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting
  2022-500967-11-00 5 2023-07-06 Previously Untreated Metastatic or Unresectable Melanoma
• Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnorma … Recruiting
  2022-501943-34-00 5 2023-06-27 Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
• Early reduction of antiplatelet therapy in patients with Acute Coronary Syndrome treated with stent implantation and at high risk of bleedin … Recruiting
  2023-509868-20-00 5 2023-06-24 Acute coronary syndrome
• A study to look at how safe divarasib is when given on its own or in combination with other anti-cancer therapies, and how well these medici … Recruiting
  2023-507171-22-00 9 2023-06-21 Untreated Advanced or Metastatic Non-Small Cell Lung Cancer
• Randomized phase 2 study of Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic P … Recruiting
  2024-518710-11-00 4 2023-06-12 Metastatic pancreatic ductal adenocarcinoma (mPDAC)
• Early phase study to evaluate the safety and efficacy of SMART101 to improve transplantation in blood cancers Recruiting
  2024-517953-28-00 7 2023-06-07 Treatment in haematopoietic stem cell transplantation
• A study to assess efficacy and safety of benralizumab in paediatric patients with severe eosinophilic asthma (severe asthma marked by high … Recruiting
  2022-501344-14-00 5 2023-06-05 Paediatric Patients with Severe Eosinophilic Asthma Asthma is a long-t
• CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in R/R PCNSL Recruiting
  2024-513312-95-00 7 2023-05-30 Part B+C. Primary central nervous system lymphoma (PCNSL)
• A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX- 880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaire … Recruiting
  2024-513929-23-00 10 2023-05-26 Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Seve
• Targeted therapy with anakinra for dilated cardiomyopathy: phase IIa randomized double blind monocentric clinical trial to evaluate the effi … Recruiting
  2024-514861-21-00 4 2023-05-25 Inflammatory dilated cardiomyopathy
• Window-of-opportunity umbrella platform trial of short-course pre-operative targeted treatments in patients with molecularly selected and re … Recruiting
  2022-501308-90-00 4 2023-05-24 Molecularly selected and resectable primary colorectal cancer
• This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a Phase 2 evaluation of elacestran … Recruiting
  2024-512878-98-00 9 2023-05-16 Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breas
• Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w … Recruiting
  2022-501808-96-00 4 2023-05-15 Mantle Cell Lymphoma
• Platform study of JDQ443 in combinations in patients with advanced solid tumors harboring the KRAS G12C mutation Recruiting
  2023-506716-41-00 9 2023-05-08 Adult patients with advanced (metastatic or unresectable) KRAS G12C mu
• The ACTION Study: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy Recruiting
  2022-502051-56-00 5 2023-04-28 H3 K27M-mutant diffuse glioma
• Study of Combination Therapies in Esophageal Cancer Recruiting
  2023-505189-26-00 9 2023-03-28 Advanced esophageal squamous cell carcinoma
• A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericigua … Recruiting
  2022-501238-52-00 10 2023-03-23 Heart failure due to systemic left ventricular systolic dysfunction
• A study investigating the use of EP0031 in patients with cancers having an abnormal RET gene. Recruiting
  2022-501636-42-00 9 2023-03-21 Advanced RET-altered malignancies
• A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participan … Recruiting
  2024-513578-23-00 4 2023-03-21 Tumors harboring BRAF alterations
• An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemi … Recruiting
  2023-507396-21-00 4 2023-03-16 transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic
• A study with eptinezumab in children and adolescents (6 to 17 years) with chronic or episodic migraine (REJOIN) Recruiting
  2022-502917-27-00 5 2023-03-07 Migraine
• phase I/II b study of atezolizumab and BEGEV as first salvage treatment in patients with relapsed or refractory Hodgkin’s lymphoma candidate … Recruiting
  2024-511631-10-00 9 2023-02-27 Hodgkin’s lymphoma
• Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non … Recruiting
  2024-518937-26-00 4 2023-02-21 Patients with non-metastatic muscle invasive bladder cancer
• A Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cut … Recruiting
  2023-505634-94-00 10 2023-02-02 Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythe

Showing 1,057–1,080 of 2,361 trials